Life Science

A potent and selective CB1 receptor antagonist (Kis = 7.8 and 7,943 nM for CB1 and CB2, respectively) less lipophilic (log P = 5.1) and therefore more water soluble than other known CB1 receptor ligands.

A potent and selective CB1 receptor antagonist (Kis = 7.8 and 7,943 nM for CB1 and CB2, respectively) less lipophilic (log P = 5.1) and therefore more water soluble than other known CB1 receptor ligands.

A potent and selective CB1 receptor antagonist (Kis = 7.8 and 7,943 nM for CB1 and CB2, respectively) less lipophilic (log P = 5.1) and therefore more water soluble than other known CB1 receptor ligands.

A synthetic intermediate useful for pharmaceutical synthesis.

A major phase I metabolite of tamoxifen, a well-known estrogen receptor antagonist in breast but partial estrogen receptor agonist in endometrium has at least a 100-fold higher affinity for estrogen receptors than tamoxifen.

A major phase I metabolite of tamoxifen, a well-known estrogen receptor antagonist in breast but partial estrogen receptor agonist in endometrium has at least a 100-fold higher affinity for estrogen receptors than tamoxifen.

A major phase I metabolite of tamoxifen, a well-known estrogen receptor antagonist in breast but partial estrogen receptor agonist in endometrium has at least a 100-fold higher affinity for estrogen receptors than tamoxifen.

A major phase I metabolite of tamoxifen, a well-known estrogen receptor antagonist in breast but partial estrogen receptor agonist in endometrium has at least a 100-fold higher affinity for estrogen receptors than tamoxifen.

An analog of GlcNAc that reversibly inhibits NCOAT (O-GlcNAcase).

An analog of GlcNAc that reversibly inhibits NCOAT (O-GlcNAcase).

An analog of GlcNAc that reversibly inhibits NCOAT (O-GlcNAcase).

A sensitive fluorogenic elastase substrate that is selectively cleaved by elastase to yield Rhodamine 110, which can be analyzed with an excitation wavelength of 485 nm and emission wavelength of 525 nm.